Pharmaceutical Research

, Volume 19, Issue 6, pp 868–874 | Cite as

Comparison of Oral Absorption and Bioavailability of Drugs Between Monkey and Human

  • Win L. Chiou
  • Paul W. Buehler


Purpose. To compare the oral absorption and bioavailability of numerous drugs with a wide variety of physicochemical and pharmacological properties between humans and monkeys and to explore potential reasons for the findings.

Methods. Data for fraction of dose absorbed (Fa) and oral absolute bioavailability (F) were obtained by an extensive Medline database search. Inclusion and exclusion criteria were the same as those reported in our previous studies. A total of 43 and 35 drugs were selected for Fa and F comparison, respectively. The time to reach peak concentration (tmax), total clearance, and nonrenal clearance were evaluated for 15, 28, and 13 drugs, respectively.

Results. Fa values in monkeys were similar or identical to those in humans. Additionally, similar tmax values were seen in monkeys and humans at comparable doses, thus indicating comparable absorption kinetics between the two species. Conversely, F values in monkeys were generally lower with coumarin being a marked exception. Both total and nonrenal clearances were evaluated and found to be generally greater in monkeys, supporting a generally higher first-pass metabolism and lower F in this species. This was also supported by published data suggesting greater in vitro hepatic drug metabolism for monkeys as compared to humans.

Conclusions. Monkeys appear to be a good predictor of Fa in humans. However, a generally lower F makes monkeys a potentially poor predictor of human F. Higher reported metabolic clearances and hepatic enzyme activities in monkeys may account for this observation.

drug absorption drug bioavailability first-pass metabolism monkey pharmacokinetics plasma clearance 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    B. Clark and D. A. Smith. Pharmacokinetics and toxicity testing. Crit. Rev. Toxicol. 12:343–385 (1984).Google Scholar
  2. 2.
    J. H. Lin. Species similarities and differences in pharmacokinetics. Drug Metab. Dispos. 23:1008–1020 (1995).Google Scholar
  3. 3.
    R. M. Feng, X. Lou, R. R. Brown, and A. Hutchaleelaha. Allometric pharmacokinetic scaling: Towards the prediction of human oral pharmacokinetics. Pharm. Res. 17:410–418 (2000).Google Scholar
  4. 4.
    W. L. Chiou. Commentary: The rate and extent of oral bioavailability vs. the rate and extent of oral absorption: Classification and recommendation of terminology. J. Pharmacokinet. Pharmacodyn. 28:3–6 (2001).Google Scholar
  5. 5.
    W. L. Chiou and A. Barve. Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm. Res. 15:1792–1795 (1998).Google Scholar
  6. 6.
    W. L. Chiou, C. Ma, S. M. Chung, Y. H. Jeong, and T. C. Wu. Similarity in the linear and non-linear oral absorption of drugs between human and rat. Int. J. Clin. Pharmacol. Ther. 38:532–539 (2000).Google Scholar
  7. 7.
    W. L. Chiou, Y. H. Jeong, S. M. Chung, and T. C. Wu. Evaluation of dog as an animal model to study the fraction of oral dose absorbed for 43 drugs in humans. Pharm. Res. 17:135–140 (2000).Google Scholar
  8. 8.
    J. C. Stevens, L. A. Shipley, J. R. Cashman, M. Vandenbranden, and S. A. Wrighton. Comparison of human and rhesus monkey in vitro phase I and phase II hepatic drug metabolism activities. Drug Metab. Dispos. 5:753–760 (1993).Google Scholar
  9. 9.
    J. E. Sharer, L. A. Shipley, M. R. Vandenbraden, S. N. Binkley, and S. A. Wrighton. Comparison of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. Drug Metab. Dispos. 23:1231–1241 (1995).Google Scholar
  10. 10.
    W. K. Sietsema. The absolute oral bioavailability of selected drugs. Int. J. Clin. Pharmacol. Ther. Toxicol. 27:179–211 (1989).Google Scholar
  11. 11.
    L. Z. Benet. S. Øie and J. B. Schwartz. Design and optimization of dosage regimines: Pharmacokinetic data. In A. Goodman-Gilman, J. G. Hardman, L. E. Limbard, P. B. Molinoff, and R. W. Ruddon (eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edition, McGraw-Hill, New York, 1996, pp. 1707–1792.Google Scholar
  12. 12.
    Physician's Desk Reference, Medical Economics Company, Monvale, New Jersey, 2001.Google Scholar
  13. 13.
    M. Gibaldi and D. Perrier. Pharmacokinetics, Marcel Dekker, New York, 1982.Google Scholar
  14. 14.
    W. L. Chiou. Commentary: We may not measure the correct wall permeability coefficient of drugs: Alternative absorptive clearance concept. J. Pharmacokinet. Biopharm. 23:323–343 (1996).Google Scholar
  15. 15.
    W. L. Chiou. Commentary: New perspectives on the theory of of permeability and resistance in the study of drug absorption and transport. J. Pharmacokinet. Biopharm. 24:433–442 (1997).Google Scholar
  16. 16.
    T. T. Kararli. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm. Drug Dispos. 16:351–380 (1995).Google Scholar
  17. 17.
    E. Chen, Z. Chen, and J. Bielawski. Prediction of oral absorption rate constant in human from in vivo rat data-applications to interspecies scaling and first-dose in man study optimization. J. Pharm. Sci. (Suppl. 1) 1:S–599 (1998).Google Scholar
  18. 18.
    S. Tannenbaum, H. Boxenbaum, and M. Mayersohn. Allometric analysis of organ extraction ratios. J. Pharm. Sci. 86:1319–1320 (1997).Google Scholar
  19. 19.
    N. J. Haskins, K. A. Waddell, G. C. Ford, P. N. Spalton, C. M. Walls, T. J. Forrest, and R. F. Palmer. The absorption of disopyramide in animals determined using a stable isotope coadministration technique. Biomed. Mass Spectrom. 7:80–83 (1980).Google Scholar
  20. 20.
    S. R. Howell, G. E. Husbands, J. A. Scatina, and S. F. Sisenwine. Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica 23:349–359 (1993).Google Scholar
  21. 21.
    S. R. Howell, D. R. Hicks, J. A. Scatina, and S. F. Sisenwine. Pharmacokinetics of venlafaxine and O-desmethylvenlafaxine in laboratory animals. Xenobiotica 24:315–327 (1994).Google Scholar
  22. 22.
    T. Kuroda, K. Namba, T. Torimaru, K. Kawashima, and M. Hayashi. Species differences in oral bioavailability of methotrexate between rats and monkeys. Biol. Pharm. Bull. 23:334–338 (2000).Google Scholar
  23. 23.
    A. Durand. J. P. Thénot, G. Bianchetti, and P. L. Morselli. Comparative pharmacokinetic profile of two imidazopyridine drugs: zolpidem and alpidem. Drug Metab. Rev. 24:239–266 (1992).Google Scholar
  24. 24.
    W. Krause and G. Kühne. Pharmacokinetics of rolipram in the rhesus and cynomolgus monkeys, the rat and the rabbit. Studies on species differences. Xenobiotica 18:561–571 (1988).Google Scholar
  25. 25.
    W. Krause, G. Kühne, U. Jakobs, and G. A. Hoyer. Biotransformation of the antidepressant D,L-rolipram. I. Isolation and identification of metabolites from rat, monkey, and human urine. Drug Metab. Dispos. 21:682–689 (1993).Google Scholar
  26. 26.
    W. Krause and G. Kühne. Biotransformation of the antidepressant D,L-rolipram. II. Metabolite patterns in man, rat, rabbit, rhesus and cynomolgus monkey. Xenobiotica 23:1277–1288 (1993).Google Scholar
  27. 27.
    T. Shimada, M. Mimura, K. Inoue, S. Nakamura, H. Oda, S. Ohmori, and H. Yamazaki. Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys and humans. Arch. Toxicol. 71:401–408 (1997).Google Scholar
  28. 28.
    J. H. Lin, M. Chiba, S. K. BalaniI, W. Chen, G. Y. Kwei, K. J. Vastag, and J. A. Nishime. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos. 24:1111–1120 (1996).Google Scholar
  29. 29.
    L. Prichard, G. Gillet, C. Bonfils, J. Domergue, J. P. Thénot, and P. Maurel. Oxidative metabolism of zolpidem by human liver cytochrome P450s. Drug Metab. Dispos. 23:1253–1262 (1995).Google Scholar
  30. 30.
    M. Chiba, J. A. Nishime, W. Neway, Y. Lin and J. H. Lin. Comparative in vitro metabolism of indinavir in primates—a unique stereoselective hydroxylation in monkey. Xenobiotica 30:117–129 (2000).Google Scholar
  31. 31.
    W. A. Ritschel, K. A. Hoffmann, H. S. Tan, and P. R. Sanders. Pharmacokinetics of coumarin upon i.v. administration in man. Arzneimittelforschung 26:1382–1387 (1976).Google Scholar
  32. 32.
    W. A. Ritschel, D. D. Denson, and K. W. Grummich. Pharmacokinetics of coumarin and 7-hydroxycoumarin in the rhesus monkey after intravenous and peroral administration. Arzneimittelforschung 38:1619–1623 (1988).Google Scholar
  33. 33.
    W. A. Ritschel, N. N. Vachharajani, R. D. Johnson, and A. S. Hussain. Interspecies scaling of the pharmacokinetic parameters of coumarin among six different mammalian species. Methods Find. Exp. Clin. Pharmacol. 13:697–702 (1991).Google Scholar

Copyright information

© Plenum Publishing Corporation 2002

Authors and Affiliations

  1. 1.Department of Pharmaceutics and Pharmacodynamics (M/C 865), College of PharmacyThe University of Illinois at ChicagoChicago

Personalised recommendations